Related Experiment Video
Updated: Nov 1, 2025
07:50
Facilitating Drug Discovery: An Automated High-content Inflammation Assay in Zebrafish
Published on: July 16, 2012
14.5K
Anti-Inflammatory Effect of Deflazacort
International Archives of Allergy and Immunology
|June 25, 2021
Summary
Deflazacort (DFZ) effectively inhibits IgE-mediated release of histamine and leukotriene C4 (LTC4) from basophils, showing comparable efficacy to dexamethasone and prednisolone. DFZ also demonstrated additive effects when combined with cyclosporin A.
Area of Science:
- Immunology
- Pharmacology
Background:
- Glucocorticoids are widely used for their anti-inflammatory properties.
- Understanding the comparative efficacy of different glucocorticoids is crucial for optimizing treatment.
- Basophils play a key role in allergic responses through mediator release.
Purpose of the Study:
- To compare the effects of deflazacort (DFZ), prednisolone (PRED), and dexamethasone (DEX) on IgE-mediated mediator release from human basophils.
- To evaluate the combined effects of DFZ and cyclosporin A (CsA) on basophil mediator release.
Main Methods:
- Human peripheral blood basophils were incubated with pharmacological concentrations of DFZ, PRED, and DEX.
- The release of preformed (histamine) and de novo synthesized (leukotriene C4 - LTC4) mediators was measured.
- Basophils were also incubated with DFZ in combination with CsA.
Main Results:
- DFZ concentration-dependently inhibited IgE-dependent histamine and LTC4 release from basophils (9-50%).
- DFZ exhibited similar anti-inflammatory efficacy to DEX and comparable efficacy and potency to PRED.
- Low concentrations of DFZ combined with CsA produced an additive inhibition of histamine and LTC4 release.
Conclusions:
- Deflazacort is an effective inhibitor of key inflammatory mediators released by basophils.
- DFZ demonstrates comparable anti-inflammatory activity to other established glucocorticoids.
- The additive effect of DFZ with CsA suggests potential synergistic therapeutic benefits in allergic conditions.
Related Concept Videos
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
258
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
258
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
299
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
299
01:29Drugs for Treatment of Ulcerative Colitis in IBD
284
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
284
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
271
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
271
01:29Inflammatory Bowel Disease IV: Pharmacological Management
254
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
254
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
1.2K
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
1.2K